Literature DB >> 8926045

Effects of adenosine on guinea pig pulmonary eosinophils.

B A Walker1.   

Abstract

Extracellular adenosine has pharmacological activity on a wide variety of cell types and may play an important role as an inflammatory modulator with both pro- and anti-inflammatory activities. These studies examine the effects of adenosine on guinea pig pulmonary eosinophils. Adenosine alone did not directly induce superoxide (O2-) production. Pretreatment with adenosine primed the O2- response of guinea pig pulmonary eosinophils following the addition of 1 or 10 microM platelet-activating factor (PAF). Priming was seen at adenosine concentrations greater than 1 microM and was maximal at 100 microM. At this maximal dose, adenosine priming increased the O2- response to 1 microM and 10 microM PAF by 86% and 51%, respectively. Priming by adenosine was not seen when ionomycin or phorbol myristate acid (PMA) were used as agonists. In fura-2 loaded eosinophils, the addition of 100 microM adenosine resulted in a small but significant rise in intracellular calcium of 54.4 +/- 9.2 nM above baseline. In contrast, similar adenosine concentrations had no effect on cytosolic calcium levels in guinea pig neutrophils. These data demonstrate a pro-inflammatory role for adenosine in elicited guinea pig pulmonary eosinophils.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8926045     DOI: 10.1007/bf01487741

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  45 in total

1.  Potentiation of mast cell mediator release by adenosine.

Authors:  D L Marquardt; C W Parker; T J Sullivan
Journal:  J Immunol       Date:  1978-03       Impact factor: 5.422

2.  Studies on the receptor mediating cyclic AMP-independent enhancement by adenosine of IgE-dependent mediator release from rat mast cells.

Authors:  M K Church; P J Hughes; C J Vardey
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

3.  Adenosine potentiates mediator release from human lung mast cells.

Authors:  P T Peachell; M Columbo; A Kagey-Sobotka; L M Lichtenstein; G Marone
Journal:  Am Rev Respir Dis       Date:  1988-11

4.  The effects of adenosine agonists on human neutrophil function.

Authors:  D J Schrier; K M Imre
Journal:  J Immunol       Date:  1986-11-15       Impact factor: 5.422

Review 5.  Inflammatory mechanisms and nocturnal asthma.

Authors:  P J Barnes
Journal:  Am J Med       Date:  1988-07-29       Impact factor: 4.965

6.  Signal transduction events in stimulated rat neutrophils: effects of adenine nucleotides.

Authors:  P A Ward; T W Cunningham; K J Johnson
Journal:  Clin Immunol Immunopathol       Date:  1989-01

7.  Bronchial challenge with adenosine causes the release of serum neutrophil chemotactic factor in asthma.

Authors:  A G Driver; C A Kukoly; W J Metzger; S J Mustafa
Journal:  Am Rev Respir Dis       Date:  1991-05

8.  Repeated antigen challenge induces airway hyperresponsiveness with tissue eosinophilia in guinea pigs.

Authors:  K Ishida; L J Kelly; R J Thomson; L L Beattie; R R Schellenberg
Journal:  J Appl Physiol (1985)       Date:  1989-09

9.  Inhibition of human monocyte TNF production by adenosine receptor agonists.

Authors:  V Le Vraux; Y L Chen; I Masson; M De Sousa; J P Giroud; I Florentin; L Chauvelot-Moachon
Journal:  Life Sci       Date:  1993       Impact factor: 5.037

10.  Adenosine promotes neutrophil chemotaxis.

Authors:  F R Rose; R Hirschhorn; G Weissmann; B N Cronstein
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

View more
  2 in total

1.  A3 adenosine receptor signaling influences pulmonary inflammation and fibrosis.

Authors:  Eva Morschl; Jose G Molina; Jonathan B Volmer; Amir Mohsenin; Ralph S Pero; Jeong-Soo Hong; Farrah Kheradmand; James J Lee; Michael R Blackburn
Journal:  Am J Respir Cell Mol Biol       Date:  2008-06-27       Impact factor: 6.914

Review 2.  Purinergic signalling and immune cells.

Authors:  Geoffrey Burnstock; Jean-Marie Boeynaems
Journal:  Purinergic Signal       Date:  2014-10-29       Impact factor: 3.765

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.